Haleon PLC Updates on Total Voting Rights and Share Capital

Haleon PLC ( (GB:HLN) ) has issued an announcement.

Haleon PLC announced that as of November 30, 2025, it has issued a total of 8,952,353,648 ordinary shares, with 45,882,158 held as treasury shares. This results in 8,906,471,490 shares with voting rights, a figure crucial for shareholders and stakeholders for notification obligations under the FCA’s rules. This announcement is significant for stakeholders as it provides clarity on voting rights and helps in regulatory compliance.

The most recent analyst rating on (GB:HLN) stock is a Sell with a £335.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s overall stock score reflects a strong financial foundation with robust profitability and cash flow, tempered by moderate technical indicators and valuation metrics. The mixed earnings call results, with regional strengths and North American challenges, further influence the score. The company’s strategic focus on innovation and geographic expansion supports a cautiously optimistic outlook.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse product portfolio across six major categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its well-known brands, such as Advil, Centrum, and Sensodyne, are based on trusted science and innovation.

Average Trading Volume: 22,050,149

Technical Sentiment Signal: Buy

Current Market Cap: £33.03B

For an in-depth examination of HLN stock, go to TipRanks’ Overview page.